Objective: Exercise training (ET) provides a cardioprotective effect against pathological cardiac hypertrophy. Nitric oxide (NO) plays an important role in modulating cardiac hypertrophy. However, few studies explore the relationship between NO signaling and the inhibitory effect of ET on pathological cardiac remodeling. Methods: In this study, we evaluated ET effects on isoproterenol (ISO)-induced cardiac hypertrophy in female mice. Moreover, L-NAME (Nω-nitro-L-arginine methyl ester), a nonselective NO synthase (NOS) inhibitor, was used to assess the involvement of NO signaling in cardiac hypertrophy. Morphological and echocardiographic variables were assessed. Cardiac hypertrophy-related gene expression was detected by real-time PCR and the protein levels of NOS signaling molecules were determined by Western blot. Results:L-NAME treatment prevented the beneficial effects of ET against the increase in heart weight (HW)/body weight (BW), HW/tibia length and lung weight/BW and echocardiographic variables following ISO injection. Also, L-NAME co-administration reversed ET-induced inhibition of myocardial fibrosis and fetal gene reactivation in ISO-treated mice. Furthermore, L-NAME treatment prevented ET-mediated up-regulation of phosphorylated endothelial NOS and plasma NO in ISO-treated mice. Conclusions: Our findings demonstrate that L-NAME treatment could abolish ET-induced cardioprotection against pathological cardiac hypertrophy and that NOS modulation may be involved in the antihypertrophic effects induced by ET.

Serra AJ, Higuchi ML, Ihara SS, Antonio EL, Santos MH, Bombig MT, Tucci PJ: Exercise training prevents beta-adrenergic hyperactivity-induced myocardial hypertrophy and lesions. Eur J Heart Fail 2008;10:534-539.
Serra AJ, Santos MH, Bocalini DS, Antonio EL, Levy RF, Santos AA, Higuchi ML, Silva JA, Magalhaes FC, Barauna VG, et al: Exercise training inhibits inflammatory cytokines and more than prevents myocardial dysfunction in rats with sustained beta-adrenergic hyperactivity. J Physiol 2010;588:2431-2442.
Giannuzzi P, Temporelli PL, Corra U, Tavazzi L; ELVD-CHF Study Group: Antiremodeling effect of long-term exercise training in patients with stable chronic heart failure: results of the Exercise in Left Ventricular Dysfunction and Chronic Heart Failure (ELVD-CHF) Trial. Circulation 2003;108:554-559.
Andersen K, Jonsdottir S, Sigurethsson AF, Sigurethsson SB: The effect of physical training in chronic heart failure (in Icelandic). Laeknabladid 2006;92:759-764.
Sanada S, Node K, Minamino T, Takashima S, Ogai A, Asanuma H, Ogita H, Liao Y, Asakura M, Kim J, et al: Long-acting Ca2+ blockers prevent myocardial remodeling induced by chronic NO inhibition in rats. Hypertension 2003;41:963-967.
Linz W, Wohlfart P, Scholkens BA, Malinski T, Wiemer G: Interactions among ACE, kinins and NO. Cardiovasc Res 1999;43:549-561.
Matsuoka H, Nakata M, Kohno K, Koga Y, Nomura G, Toshima H, Imaizumi T: Chronic L-arginine administration attenuates cardiac hypertrophy in spontaneously hypertensive rats. Hypertension 1996;27:14-18.
Ozaki M, Kawashima S, Yamashita T, Hirase T, Ohashi Y, Inoue N, Hirata K, Yokoyama M: Overexpression of endothelial nitric oxide synthase attenuates cardiac hypertrophy induced by chronic isoproterenol infusion. Circ J 2002;66:851-856.
Massion PB, Dessy C, Desjardins F, Pelat M, Havaux X, Belge C, Moulin P, Guiot Y, Feron O, Janssens S, Balligand JL: Cardiomyocyte-restricted overexpression of endothelial nitric oxide synthase (NOS3) attenuates beta-adrenergic stimulation and reinforces vagal inhibition of cardiac contraction. Circulation 2004;110:2666-2672.
Jones SP, Greer JJ, van Haperen R, Duncker DJ, de Crom R, Lefer DJ: Endothelial nitric oxide synthase overexpression attenuates congestive heart failure in mice. Proc Natl Acad Sci U S A 2003;100:4891-4896.
Napoli C, Williams-Ignarro S, De Nigris F, Lerman LO, Rossi L, Guarino C, Mansueto G, Di Tuoro F, Pignalosa O, De Rosa G, et al: Long-term combined beneficial effects of physical training and metabolic treatment on atherosclerosis in hypercholesterolemic mice. Proc Natl Acad Sci U S A 2004;101:8797-8802.
Calvert JW, Condit ME, Aragon JP, Nicholson CK, Moody BF, Hood RL, Sindler AL, Gundewar S, Seals DR, Barouch LA, Lefer DJ: Exercise protects against myocardial ischemia-reperfusion injury via stimulation of beta(3)-adrenergic receptors and increased nitric oxide signaling: role of nitrite and nitrosothiols. Circ Res 2011;108:1448-1458.
Kurisu S, Ozono R, Oshima T, Kambe M, Ishida T, Sugino H, Matsuura H, Chayama K, Teranishi Y, Iba O, et al: Cardiac angiotensin II type 2 receptor activates the kinin/NO system and inhibits fibrosis. Hypertension 2003;41:99-107.
Yang L, Jia Z, Zhu M, Zhang J, Liu J, Wu P, Tian W, Li J, Qi Z, Tang X: Exercise protects against chronic beta-adrenergic remodeling of the heart by activation of endothelial nitric oxide synthase. PLoS One 2014;9:e96892.
Drexler H: Nitric oxide synthases in the failing human heart: a doubled-edged sword? Circulation 1999;99:2972-2975.
Krenek P, Kmecova J, Kucerova D, Bajuszova Z, Musil P, Gazova A, Ochodnicky P, Klimas J, Kyselovic J: Isoproterenol-induced heart failure in the rat is associated with nitric oxide-dependent functional alterations of cardiac function. Eur J Heart Fail 2009;11:140-146.
Zhang P, Xu X, Hu X, van Deel ED, Zhu G, Chen Y: Inducible nitric oxide synthase deficiency protects the heart from systolic overload-induced ventricular hypertrophy and congestive heart failure. Circ Res 2007;100:1089-1098.
Hu A, Jiao X, Gao E, Koch WJ, Sharifi-Azad S, Grunwald Z, Ma XL, Sun JZ: Chronic beta-adrenergic receptor stimulation induces cardiac apoptosis and aggravates myocardial ischemia/reperfusion injury by provoking inducible nitric-oxide synthase-mediated nitrative stress. J Pharmacol Exp Ther 2006;318:469-475.
Quindry JC, French J, Hamilton KL, Lee Y, Selsby J, Powers S: Exercise does not increase cyclooxygenase-2 myocardial levels in young or senescent hearts. J Physiol Sci 2010;60:181-186.
Bachhav SS, Bhutada MS, Patil SD, Baser B, Chaudhari KB: Effect of Viscum articulatum Burm. (Loranthaceae) in Nω-nitro-L-arginine methyl ester induced hypertension and renal dysfunction. J Ethnopharmacol 2012;142:467-473.
Ribeiro MO, Antunes E, de Nucci G, Lovisolo SM, Zatz R: Chronic inhibition of nitric oxide synthesis. A new model of arterial hypertension. Hypertension 1992;20:298-303.
Pfeiffer S, Leopold E, Schmidt K, Brunner F, Mayer B: Inhibition of nitric oxide synthesis by NG-nitro-L-arginine methyl ester (L-NAME): requirement for bioactivation to the free acid, NG-nitro-L-arginine. Br J Pharmacol 1996;118:1433-1440.
Kuru O, Senturk UK, Kocer G, Ozdem S, Baskurt OK, Cetin A, Yesilkaya A, Gunduz F: Effect of exercise training on resistance arteries in rats with chronic NOS inhibition. J Appl Physiol (1985) 2009;107:896-902.
Vergely C, Perrin-Sarrado C, Clermont G, Rochette L: Postischemic recovery and oxidative stress are independent of nitric-oxide synthases modulation in isolated rat heart. J Pharmacol Exp Ther 2002;303:149-157.
Sampaio RC, Tanus-Santos JE, Melo SE, Hyslop S, Franchini KG, Luca IM, Moreno H Jr: Hypertension plus diabetes mimics the cardiomyopathy induced by nitric oxide inhibition in rats. Chest 2002;122:1412-1420.
Suda O, Tsutsui M, Morishita T, Tanimoto A, Horiuchi M, Tasaki H, Huang PL, Sasaguri Y, Yanagihara N, Nakashima Y: Long-term treatment with N(omega)-nitro-L-arginine methyl ester causes arteriosclerotic coronary lesions in endothelial nitric oxide synthase-deficient mice. Circulation 2002;106:1729-1735.
Darblade B, Batkai S, Causse E, Gourdy P, Fouque MJ, Rami J, Arnal JF: Failure of L-nitroarginine to inhibit the activity of aortic inducible nitric oxide synthase. J Vasc Res 2001;38:266-275.
Gao F, Gao E, Yue TL, Ohlstein EH, Lopez BL, Christopher TA, Ma XL: Nitric oxide mediates the antiapoptotic effect of insulin in myocardial ischemia-reperfusion: the roles of PI3-kinase, Akt, and endothelial nitric oxide synthase phosphorylation. Circulation 2002;105:1497-1502.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.